{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:47:07Z","timestamp":1787827627038,"version":"build-2784847793"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.gore.2026.102027","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:01:40Z","timestamp":1767891700000},"page":"102027","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Successful use of immune checkpoint Inhibition in a patient with myasthenia gravis and recurrent endometrial cancer- expanding access beyond initial clinical trial eligibility"],"prefix":"10.1016","volume":"63","author":[{"given":"Olivia N.","family":"Julian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"Christofsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2101-1935","authenticated-orcid":false,"given":"Ramez N.","family":"Eskander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10391","key":"10.1016\/j.gore.2026.102027_b0005","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","article-title":"Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of22 million individualsin the UK","volume":"401","author":"Conrad","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.gore.2026.102027_b0010","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/annonc\/mdz445","article-title":"When isoff-labeloff-road?","volume":"30","author":"e Vries","year":"2019","journal-title":"Ann. Oncol."},{"issue":"23","key":"10.1016\/j.gore.2026.102027_b0015","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.gore.2026.102027_b0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.13727","article-title":"Immune Checkpoint Inhibitors for patientsWithPreexisting Autoimmune Neurologic Disorders","volume":"8","author":"Fletcher","year":"2025","journal-title":"JAMA Netw. Open"},{"issue":"12","key":"10.1016\/j.gore.2026.102027_b0025","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.3390\/medicina59122152","article-title":"Plasmapheresis in the ICU","volume":"59","author":"Hussein","year":"2023","journal-title":"Medicina (Kaunas)"},{"issue":"2","key":"10.1016\/j.gore.2026.102027_b0030","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patientswithadvanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.gore.2026.102027_b0035","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia Gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.gore.2026.102027_b0040","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann. Oncol."},{"issue":"23","key":"10.1016\/j.gore.2026.102027_b0045","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimabfor primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gore.2026.102027_b0050","doi-asserted-by":"crossref","unstructured":"Moradi L, Curtis A et.al., 2021. Durable Metastatic Melanoma Remission following pembrolizumab and radiotherapy: a case report of prophylactic immunosuppression in a patient with myasthenia gravis and immune mediated colitis. Frontiers in Immunology.12 (1-6). doi 10.3389\/fimmu.2021.78499.","DOI":"10.3389\/fimmu.2021.788499"},{"key":"10.1016\/j.gore.2026.102027_b0055","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J. Immunotherapy Cancer"},{"issue":"3","key":"10.1016\/j.gore.2026.102027_b0060","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab Plus Carboplatin\/Paclitaxel Followed by Maintenance DurvalumabWithor without Olaparib as First\u2013Line Treatment for Advanced Endometrial Cancer: the phase III DUO\u2013E Trial","volume":"42","author":"Westin","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2026.102027_b0065","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s40425-019-0626-9","article-title":"Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?","volume":"7","author":"Zaremba","year":"2019","journal-title":"J. Immunother. Cancer"}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235257892600007X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235257892600007X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:21:37Z","timestamp":1771662097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235257892600007X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":13,"alternative-id":["S235257892600007X"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2026.102027","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful use of immune checkpoint Inhibition in a patient with myasthenia gravis and recurrent endometrial cancer- expanding access beyond initial clinical trial eligibility","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2026.102027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102027"}}